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Abstract
Background: Hypertension is an important risk factor for cardiovascular disease, even in the elderly. Fimasartan is a
new non-peptide angiotensin II receptor blocker with a selective type I receptor blocking effect. The objective of
this study is to confirm the safety and the non-inferiority of the blood pressure–lowering effect of fimasartan
compared with those of perindopril, which has been proven safe and effective in elderly patients with hypertension.
Methods: This is a randomized, double-blind, active-controlled, two-parallel group, optional-titration, multicenter,
phase 3 study comparing the efficacy and safety of fimasartan and perindopril arginine. The study population consists
of individuals 70 years old or older with essential hypertension. The primary outcome will be a change in sitting systolic
blood pressure from baseline after the administration of the investigational product for 8 weeks. The secondary
outcomes will be a change in sitting diastolic blood pressure from baseline and changes in sitting systolic blood
pressure and diastolic blood pressure from baseline after the administration of the investigational product for 4, 16, and
24 weeks. The sample size will be 119 subjects for each group to confer enough power to test for the primary
outcome.
Discussion: Research to confirm the efficacy and safety of a new medicine compared with those of previously proven
anti-hypertensive drugs is beneficial to guide physicians in the selection of therapeutic agents. If it is confirmed that
the new drug is not inferior to the existing drug, the drug will be considered as an option in the treatment
of hypertension in elderly patients.
Trial registration: ClinicalTrials.gov Identifier: NCT03246555, registered on July 25, 2017.
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Background
Hypertension is a major risk factor for cardiovascular
disease and affects over 1 billion people worldwide.
From 1998 to 2014, the prevalence of hypertension in
the population older than 65 years was 55.3–60.5% in
Korea; thus, over half of the elderly individuals have
hypertension. It is important to note that hypertension
treatment can lower the risk of stroke, cardiovascular
disease, and mortality [1, 2]. When a stroke or cardio-
vascular disease occurs, the quality of life and the daily
life of the elderly are greatly affected. Therefore, there is
an urgent need to study the treatment of hypertension
in elderly individuals.
The Eighth Report of the Joint National Committee on
the Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure aims to achieve a systolic blood
pressure (SBP) of less than 150 mm Hg and a diastolic
blood pressure (DBP) of less than 90 mm Hg in people
older than 60 years [3]. There are differences among the
guidelines, but the SBP target, in general, is set at less
than 140–150 mm Hg. Angiotensin-converting enzyme
(ACE) inhibitors, angiotensin II receptor blockers
(ARBs), calcium channel blockers, and diuretics are rec-
ommended as first-line treatments for essential hyper-
tension in elderly individuals without comorbidities.
Among these, ACE inhibitors and ARBs have been
proven to be clinically effective in the treatment of
hypertension, as well as heart failure, by acting on the
renin–angiotensin system, which acts as a main cause
mechanism in cardiovascular disease [4].
The objective of this study is to confirm the safety
and the non-inferiority of the blood pressure–lower-
ing effect of fimasartan compared with those of peri-
ndopril in elderly individuals with essential
hypertension. Perindopril arginine, selected as a con-
trol drug, is an ACE inhibitor used in the Hyperten-
sion in the Very Elderly Trial [2], a representative
clinical study evaluating the effects of hypertension
treatment in elderly patients older than 80 years. In
the study, the mean blood pressure while sitting was
15.0/6.1 mm Hg lower in the active-treatment group
than in the placebo group and fewer serious adverse
events were reported in the active-treatment group.
Based on these findings, perindopril was considered
to be safe and effective when administered to elderly
individuals. Fimasartan is a new non-peptide ARB
with selective type I receptor blocking effect, which
has been proven to be clinically effective in many
randomized controlled trials [5, 6]. However, there are
no clinical trials evaluating the efficacy and safety of
this drug in patients over 70 years old. The response
of elderly patients to medication may differ from that
of the adult patient because the physiological changes
due to aging affect the absorption, distribution,
metabolism, and elimination of drugs [7]. As a result,
the efficacy and safety of the drug may be different.
For example, a study on risedronate has shown that
risedronate has no significant effect on preventing hip
fractures in women over 80 years of age [8]. There-
fore, we would like to confirm the efficacy and safety
of fimarsartan in elderly patients through a random-
ized, double-blind, multicenter trial.
Older patients are highly heterogeneous, and physio-
logical ability and vulnerability vary widely, even for in-
dividuals of the same age [9]. Frailty, as a reflection of
decreased physiologic reserve, is closely associated with
biological age [10], concurrent medical conditions, mor-
bidity, and decreased survival in elderly individuals [11].
Frailty assessments are clinically useful to address the
heterogeneity of the health status among elderly individ-
uals. The K-FRAIL test [12] and gait speed measurement
[13], which are known to be useful methods for screen-
ing the frailty status, will be performed on the subjects,
considering that the blood pressure–lowering effect of
the anti-hypertensive drug may be different according to
the frailty status. Using these results, we will analyze
whether there is any difference in blood pressure–lower-
ing effect according to the frailty status.
Methods
Study design
This is a randomized, double-blind, active-controlled,
two-parallel group, optional-titration, multicenter, phase
3 study designed to evaluate the blood pressure–lower-
ing effect and safety of fimasartan and perindopril in eld-
erly individuals with essential hypertension. The flow
chart below captures the main events during the study
(Fig. 1), and the time line of the study/outcome assess-
ments is outlined in Fig. 2.
Study population
Elderly with essential hypertension
Inclusion criteria are as follows:
1) Voluntarily provided written consent to participate
in this clinical study after receiving an explanation
of this study
2) Elderly (70 years old or older)
3) At the screening visit (Visit 1),
 Blood pressure: The mean blood pressure measured
three times on the selected arm, as below:
 For treatment-naïve patients who have not taken
drugs for hypertension within the last 3 months
from the screening visit: mean siSBP (sitting sys-
tolic blood pressure) of at least 140 mm Hg
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 For patients with essential hypertension who are
taking drugs for hypertension: mean siSBP of at least
130 mm Hg
4) At the baseline visit (Visit 2),
 Blood pressure: Patients with mild to moderate
essential hypertension whose mean siSBP measured
three times on the selected arm is at least 140 mm
Hg
 Patients with treatment compliance of at least 70%
during the placebo run-in period
5) Capable of understanding written instructions,
cooperative, and able to participate until the end of
the clinical study.
Exclusion criteria are as follows:
1) Severe hypertension with mean siSBP of at
least 180 mm Hg or siDBP (sitting diastolic blood
pressure) of at least 110 mm Hg (office blood
pressure) at the screening visit (Visit 1) and
baseline visit (Visit 2). (However, at screening, it is
based on the blood pressures measured from both
arms, and the patient is excluded if the result from
either of the arms falls within the criteria.)
2) Patients with a difference in siSBP of at least 20 mm
Hg and siDBP of at least 10 mm Hg in the selected
arm at the screening visit (Visit 1)
3) Patients with a history of secondary hypertension
and any history of suspected secondary
hypertension but not limited to the following
conditions: coarctation of the aorta, primary
hyperaldosteronism, renal artery stenosis, Cushing’s
syndrome, pheochromocytoma, or polycystic kidney
disease
4) Orthostatic hypotension with symptoms
5) Patients with insulin-dependent diabetes mellitus or
uncontrolled diabetes mellitus (hemoglobin A1c
[HbA1c] of more than 9.0% at the screening visit;
Visit 1)
6) Patients with a history of malignant tumor,
including leukemia and lymphoma, within the past
5 years (however, participation is allowed if it has
not recurred for at least 5 years after a tumor
surgery)
7) Patients with any chronic inflammatory disease
requiring chronic anti-inflammatory treatment,
consumption disease, autoimmune disease such as
rheumatoid arthritis and systemic lupus erythema-
tosus, or connective tissue disease at present or in
the past
8) Patients with a history of a hypersensitivity reaction
to any component of the investigational product
and similar compounds: renin–angiotensin system
inhibitors, ACE inhibitors, thiazide diuretics and
sulfonamides, Yellow 5 (Sunset Yellow FCF (dye)),
etc.
9) Patients with hyperlipidemia undergoing low-
density lipoprotein (LDL) apheresis (patients under-
going LDL hemapheresis using a dextran sulfate
cellulose)
10) Patients on dialysis, post-renal transplantation pa-
tients, or patients with clinically significant renal
and hepatic diseases, such as cirrhosis, biliary tract
obstruction, cholestasis, liver failure, and hepatic
Fig. 1 Study overview. Abbreviations: FMS Fimasartan, HCTZ Hydrochlorothiazide, PCB Placebo, Perind Perindopril arginine, Inda Indapamide, R Randomization,
S Screening
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encephalopathy, or the following findings from tests
at screening (Visit 1):
 Creatinine clearance (the modification of diet in
renal disease (MDRD) equation) of less than 30 mL/
min
 Alanine transaminase (ALT) or aspartate
transaminase (AST) of at least three times the upper
limit of normal (ULN)
 Hypokalemia (<3.5 mmol/L), hyponatremia (<133
mmol/L), or hyperkalemia (>5.5 mmol/L)
11) Patients with diagnosis of any of the following
diseases or treatment for the following diseases
within 6 months from the date of screening visit,
which is deemed to be clinically significant by the
investigator:
Fig. 2 Time line of study procedure and outcome assessment. Abbreviations: FMS Fimasartan, HCTZ Hydrochlorothiazide, Inda Indapamide, Perind
Perindopril arginine
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 Severe heart diseases: heart failure (New York Heart
Association (NYHA) class III and IV), ischemic
heart disease (angina pectoris or myocardial
infarction), peripheral vascular disease, percutaneous
transluminal coronary angioplasty, or coronary
artery bypass grafting
 Hypertrophic obstructive cardiomyopathy, severe
obstructive coronary artery disease, aortic stenosis,
or hemodynamically significant aortic or mitral
stenosis
 Clinically significant ventricular tachycardia, atrial
fibrillation, atrial flutter, or arrhythmia
 Severe cerebrovascular disease (stroke, cerebral
infarction, or cerebral hemorrhage)
 Known moderate or malignant retinopathy, such as
retinal bleeding, visual disturbance, and retinal
microaneurysm
12) Patients with angioedema caused by drugs,
including ACE inhibitors, hereditary or idiopathic
angioedema, or a history of such diseases
13) Patients with a history of alcohol or drug abuse
within the last 2 years
14) Surgical or medical diseases that may affect the
absorption, distribution, metabolism, and excretion
of drugs that fall under one of the following cases
(but not limited to them): history of major
gastrointestinal surgery, such as gastrectomy,
gastroenterostomy or small bowel resection,
gastrointestinal bypass and gastrointestinal stapling,
active gastritis, gastrointestinal or rectal bleeding at
present, and active inflammatory bowel syndrome
within the last 12 months
15) Patients with volume depletion, anuria, and shock
16) Patients with hereditary disorders of galactose
intolerance, Lapp lactase deficiency, or glucose–
galactose malabsorption
17) Patients who used other investigational products
within 12 weeks prior to screening
18) Patients with any other reason that, in the opinion
of the investigator, may contraindicate participation
in the study.
Study interventions
The treatment in this clinical study starts with fimasar-
tan 30mg or perindopril arginine 2.5 mg; if blood pres-
sure is not controlled (siSBP of at least 140 mm Hg or
siDBP of at least 90 mm Hg), the dose is escalated once
gradually and then a diuretic combination is adminis-
tered. The escalation of dose and administration of di-
uretics are decided after checking blood pressure 4
weeks after the initiation of each investigational product.
Screening/placebo run-in period (single-blind)
If a subject voluntarily consents to participate in the
study, the investigator will perform screening tests and a
medical history survey to assess the subject’s eligibility.
As a result of the screening tests, all subjects who are in
compliance with the inclusion criteria and do not fulfill
the exclusion criteria will have a placebo run-in period
of 3–5 weeks and those who are on anti-hypertensive
medications will stop the existing anti-hypertensive
medication and take the placebo. The placebo run-in
period proceeds on a single-blind basis.
Dose titration period (double-blind)
After the completion of the placebo run-in period, assess-
ments are performed to select the final subjects at the
baseline visit, and the eligible subjects are randomly
assigned to the fimasartan 30mg group or the perindopril
arginine 2.5mg group at a 1:1 ratio. The randomly
assigned subjects take two tablets of the relevant investiga-
tional product for each treatment group once daily for 4
weeks; in the case of patients with uncontrolled blood
pressure (siSBP of at least 140mm Hg or siDBP of at least
90mm Hg) after 4 weeks, the dose is doubled (fimasartan
60mg or perindopril arginine 5mg) through an optional
titration. The subjects take the investigational product at
the escalated dose once daily for 4 weeks, and the patients
still with uncontrolled blood pressure after the 4-week ad-
ministration of the escalated dose take a diuretic combin-
ation (fimasartan 60mg/hydrochlorothiazide 12.5mg or
perindopril arginine 5mg/indapamide 1.25mg) addition-
ally. After 8 weeks, changes in their blood pressure are
checked.
Extension period (open-label)
The patients with controlled blood pressure (siSBP of
less than 140 mm Hg and siDBP of less than 90mm Hg)
at week 16 participate in the 8-week open-label exten-
sion study after the dose for the test group is switched
back to the previous dose and the dose for the control
group is switched to the dose for the test group, and the
efficacy and safety of the drugs are evaluated.
In the course of the clinical study, the subjects will
make visits, including the screening and baseline visits,
at weeks 4, 8, and 16 as well as at week 24 during the
extension study (in the case of patients with controlled
blood pressure at week 16), and they will undergo tests
and assessments specified in the protocol at each visit.
Study outcomes
The primary outcome will be a change in siSBP from
baseline after the administration of the investigational
product for 8 weeks.
The secondary outcomes will be as follows:
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1) A change in siSBP from baseline after the
administration of the investigational product for 4,
16, and 24 weeks
2) A change in siDBP from baseline after the
administration of the investigational product for 4,
8, 16, and 24 weeks
3) Blood pressure response rate (siSBP of less than
140 mm Hg or decrease of siSBP of at least 20 mm
Hg after the administration for 4, 8, and 16 weeks
compared with baseline) and blood pressure
normalization rate after the administration of the
investigational products for 4, 8, and 16 weeks
(siSBP of less than 140 mm Hg and siDBP of less
than 90 mm Hg)
4) A change from baseline in the differences in
standing SBP and DBP compared with their sitting
measurements after the administration of the
investigational product for 4, 8, 16, and 24 weeks.
5) Changes in siSBP and siDBP from baseline after the
administration for 4, 8, 16, and 24 weeks depending
on the level of senescence (healthy stage, pre-
senescent stage, and senescent stage) evaluated by
K-FRAIL
6) Changes in siSBP and siDBP from baseline after the
administration for 4, 8, 16, and 24 weeks depending
on gait speed (5-m walk test, <6 s, ≥6 s)
The change will be calculated by subtracting the base-
line value from the value at the time of evaluation.
Randomization
In this clinical trial, which is double-blinded, a
randomization table is prepared by a stratified block
randomization method where a study site is the stratifica-
tion factor. For randomization, an independent statistician
will generate randomization numbers by using SAS ver-
sion 9.3 and will deliver them in an encrypted file to the
director of investigational product packaging and IWRS
(Interactive Web-based Response System) manager.
Subjects who meet all of the inclusion criteria and
none of the exclusion criteria will be randomly assigned
at a ratio of 1:1 to one of the following groups: treat-
ment group (fimasartan 30 mg) or control group (peri-
ndopril 2.5 mg). Randomization will be carried out using
IWRS.
For packaging and labeling of the investigational prod-
ucts, the sponsor’s investigational product packaging dir-
ector will be in charge of properly packaging the study
group and control group in accordance with the
randomization table and labeling on the investigational
product. The investigator will assign the randomization
numbers through IWRS to the eligible subjects on the
basis of the inclusion/exclusion criteria in the order of
enrollment in the study and will prescribe the applicable
investigational products. When dispensing the investiga-
tional products, the clinical trial pharmacist will recon-
firm whether the subject’s randomization number
matches the number labeled on the investigational
product.
Blinding
In the placebo run-in period and dose titration period of
this study, a placebo with the same formulation and
properties that is not distinguished by appearance is
used to maintain double blindness. The tester, test sub-
jects, and monitor personnel are not informed about
which group the test subjects are assigned to.
In an emergency situation that threatens the safety of
the subject, the investigator should promptly notify the
person in charge of unblinding from Boryung Pharma-
ceutical Co., Ltd. (Seoul, South Korea). The person in
charge of unblinding should decide whether to unblind
in consultation with the investigator and document the
decision. After consulting with the client, the investiga-
tor accesses the webpage about random assignment.
After inputting the required information, the investiga-
tor confirms the clinical trial drug information of the
subject and documents the unblinding. However, sub-
jects and monitor personnel are not informed about
unblinding. When the trial is over and the database is
confirmed to be complete and accurate, the data will be
locked and the random assignment code information
will be released after the unblinding procedure.
Sample size and statistical analysis
Sample size
In existing non-inferiority clinical trials of anti-
hypertensive agents comparing the lowering effect of
siSBP, the non-inferiority margin (δ) is set to 5–6mm
Hg [14, 15]. In this study, the non-inferiority margin was
set at 5 mm Hg. As the standard deviation was 12.52 to
12.53 mm Hg in the fimasartan clinical trial for adult pa-
tients, the standard deviation (σ) was assumed to be 13
mm Hg in this study. Given a unilateral significance
level of 2.5%, a power of 80%, and 1:1 allocation, the fol-









ε ¼ μ−μ ¼ 0
δ: non-inferiority margin (5 mm Hg)
K: test group and control group allocation ratio (1:1)
α = 0.025, β = 0.2
σ = 13 mm Hg.
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The required number of subjects for each group, cal-
culated from the above formula, is 107. In consideration
of a 10% dropout rate, a total of 238 subjects, 119 from
each group, will be registered for enrollment.
Efficacy
In this clinical trial, the efficacy evaluation will analyze
mainly the data by per-protocol. We will analyze the ef-
fect of the drug on the subjects who have completed the
trial without any serious violation of the plan.
Primary efficacy evaluation
To test the difference between the test group and the
control group, an analysis of covariance (ANCOVA) will
be performed with the baseline values as covariates and
the treatment groups as effects. Change in siSBP from
baseline after the administration of the investigational
product for 8 weeks will be analyzed, and the difference
between the treatment groups will be calculated by sub-
tracting the change in the perindopril group from the
change in the fimasartan group. The fimasartan group is
determined to be non-inferior to the perindopril argin-
ine group if the lower limit of the two-sided 95% confi-
dence interval corresponding to the least square means
(LSM) difference between the treatment groups is
greater than −5 mm Hg.
Secondary efficacy evaluation
To test the difference between the groups, continuous
variables will be analyzed through an ANCOVA with the
baseline values as covariates and the treatment groups
as effects. In the case of categorical variables, the fre-
quencies (N) and percentages (%) of each period and
their two-sided 95% confidence intervals will be pre-
sented; for an intergroup difference, logistic regression
analysis will be performed with the baseline values as co-
variates. For the analysis of the changes within the treat-
ment groups at week 24, a one-sample t test or a
Wilcoxon signed-rank test will be performed.
In the subgroup analysis, the subjects will be di-
vided into three groups, such as healthy stage, pre-
senescent stage, and senescent stage, depending on
the level of senescence evaluated by K-FRAIL. The
subjects will also be divided into two groups, such as
normal gait speed group and slow gait speed group,
depending on gait speed evaluated by the 5-m walk
test. For each subgroup, the descriptive statistics for
the baseline values and the measurements at 4, 8, 16,
and 24 weeks are presented. At 4, 8, and 16 weeks
after the administration of clinical trial drugs, the
change will be analyzed through an ANCOVA with
the baseline values as covariates and the treatment as
effects. For the analysis of the changes within the
treatment groups at 24 weeks, a one-sample t test or
a Wilcoxon signed-rank test will be performed. Using
these results, we will analyze whether there is any dif-
ference in blood pressure–lowering effect according
to the frailty status.
Safety
Adverse events are coded and organized by using the
MedDRA (Medical Dictionary for Regulatory Activities;
version 19.0 or later), and the proportion of the subjects
who have experienced adverse events and the 95% confi-
dence interval are presented by treatment group. All ad-
verse events are organized according to severity, and
investigational product-related adverse events and ser-
ious adverse events are summarized separately. The chi-
squared test or the Fisher’s exact test will be used to de-
termine whether there is any difference in the incidence
of adverse events between the groups.
For continuous data, such as hematology and blood
chemistry results, the descriptive statistics (mean, stand-
ard deviation, median, minimum, maximum, etc.) will be
presented by treatment group and visit; for categorical
data, such as urinalysis and physical examination, the
frequency (N) and percentage (%) will be presented by
category. With regard to the difference in the continu-
ous data before and after administration of the investiga-
tional product, the difference among visits will be tested
by performing a paired t test or the Wilcoxon’s signed-
rank test within the treatment group. A two-sample t
test and a Wilcoxon rank-sum test will be carried out to
test the difference in the change after the administration
between the treatment groups. For the categorical vari-
ables, McNemar’s test will be performed for the
intragroup change.
Blood pressure measurements
Electronic blood pressure monitors (Omron HEM-
7080IC, Omron Corporation, Kyoto, Japan) are used to
measure blood pressure, and all laboratories use the
same product. The blood pressure of both arms is mea-
sured by a trained study coordinator at the screening
visit, and the arm with the higher average SBP obtained
by three measurements is selected as the reference arm.
Blood pressure of the upper arm of the subject is mea-
sured in the sitting position at each visit. After the sub-
ject has rested in a sitting position for at least 5 min in a
chair that can support the back and the arm has been
fixed to the heart level, the blood pressure is measured.
Blood pressure should be measured three times at inter-
vals of more than 2min, and to measure blood pressure
at the lowest drug concentration, blood pressure mea-
surements should be performed in the morning, before
dosing.
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Data collection and management
Study data are collected and managed via the Medidata
Rave™ (Medidata Solutions, Inc., New York, NY, USA,
http://www.mdsol.com) electronic data capture (EDC)
system.
Discussion
Anti-hypertensive agents are widely used because of the
high prevalence of hypertension and the clear effects of
treatment. There are various anti-hypertensive drugs,
such as diuretics, ARBs, ACE inhibitors, beta-blockers,
and calcium channel blockers. Among these, ARBs and
ACE inhibitors are the primary anti-hypertensive agents
that reduce the activity of the renin–angiotensin system.
As a result, direct vasoconstriction is blocked, sodium
retention is reduced, and blood pressure is lowered.
Important factors to consider when choosing an anti-
hypertensive agent are blood pressure–lowering effects
and side effects. Sufficient blood pressure–lowering ef-
fect is very important because strict control of blood
pressure has the advantage of lowering the risk of devel-
oping cardiovascular disease and mortality [16]. It is also
advantageous in that drug compliance can be increased
if the blood pressure can be sufficiently lowered by only
one medication. We should also look at the side effects
of the drugs. ACE inhibitors have side effects of dry
cough and angioedema related to the increase in brady-
kinin levels, and ACE inhibitors and ARBs inhibit the
synthesis of aldosterone, resulting in side effects of
hyperkalemia. Consideration should be given to the
choice of medicine, in view of the inherent side effects
of individual drugs.
Because the prevalence of hypertension increases with
age, research to confirm the efficacy and safety of new
medicines compared with previously proven anti-
hypertensive drugs for elderly individuals is beneficial
for physicians to select appropriate medications. In par-
ticular, confirming the efficacy and safety of ARBs, which
are used as the first-line drug in hypertension treatment,
may be very helpful in selecting the appropriate medica-
tion. Adding diuretics as a second agent to patients
whose blood pressure is not controlled despite an in-
creased ACE inhibitor or ARB dose is an effective way
to control blood pressure [17]. In addition, more infor-
mation on drug safety for elderly individuals can be ob-
tained by administering fimasartan or a combination of
fimasartan and hydrochlorothizide for 8 weeks to all sub-
jects during the open-label extension period.
There is an epidemiological study showing the differ-
ence in the rate of hypertension control according to the
frailty status [18]. Therefore, it is meaningful to check
whether the blood pressure–lowering effect of each drug
is different depending on the frailty status. If an anti-
hypertensive drug is less effective among the frail elderly
people, blood pressure needs to be lowered sufficiently
to the target using methods such as increasing drug dos-
age or using a combination drug.
Hypertension is widespread among elderly individuals,
and hypertension treatment is effective in reducing car-
diovascular disease and mortality. It is clinically signifi-
cant to perform randomized controlled trials to confirm
the efficacy and safety of fimasartan, which can be used
as a first-line drug for hypertension treatment in elderly
individuals. If fimasartan is not inferior to an ACE in-
hibitor that has been proven effective and safe, the drug
will be considered as an option in the treatment of
hypertension in elderly patients (Additional file 1).
Trial status
Recruitment of patients started on August 7, 2017, and
131 subjects (55%) were randomly assigned as of May
17, 2018. Protocol version number 4.1. Date: November
6, 2017.
Additional file
Additional file 1: SPIRIT 2013 checklist: Recommended items to address
in a clinical trial protocol and related documents. (DOC 124 kb)
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